Trial Finds Remdesivir As Beneficial COVID-19 Drug, NIH Says

Remdesivir may benefit COVID-19 patients not requiring ventilation, reducing recovery time by four days compared to a placebo, according to an NIH study. The study, published in the New England Journal of Medicine, found a lower mortality rate for those on Remdesivir. However, the NIH suggests Remdesivir alone is insufficient, recommending further research for complementary treatments. Early treatment initiation is crucial. Gilead Sciences' drug has shown moderate success in past trials.

What did the NIH conclude about the sufficiency of Remdesivir as a treatment?

What is the recommended timing for starting treatment to effectively fight the virus?